Where others have failed will Atl1102 succeed ?, page-458

From our spring 2018 issue of Care and Cure magazine, learn more about the pharmaceutical company Pfizer pulling out of neuroscience research.In January, news hit the headlines that pharmaceutical company Pfizer is pulling out of neuroscience research.This means that it will no longer work on potential treatments for dementia including Alzheimer’s and other conditions such as Parkinson’s.Pfizer came to this decision after a number of setbacks in its research. This included the failure in 2012 of the drug bapineuzumab to help people in the mild to moderate stages of Alzheimer’s. Dr James Pickett, Head of Research at Alzheimer’s Society, described the move as, ‘A heavy blow to the estimated 46.8 million people currently living with dementia across the globe.’This is not a reason to lose hope. Financial giant KPMG thinks other companies are unlikely to give up, saying, ‘It’s too big a market to ignore. People are going to continue to go after it despite roadblocks.’